Back to Search Start Over

High expression of S100A8 gene is associated with drug resistance to etoposide and poor prognosis in acute myeloid leukemia through influencing the apoptosis pathway

Authors :
Chien-Shing Chen
Ye Zhao
Zi-Xing Chen
Jiannong Cen
Shuiyan Wu
Ming-ying Zhang
Qi Zhou
Wen-ge Guo
Shaoyan Hu
Jian Pan
Wen-hua Yan
Weiying Gu
Xiao-yan Yang
Source :
OncoTargets and therapy
Publication Year :
2016
Publisher :
Dove Press, 2016.

Abstract

Xiao-yan Yang,1,* Ming-ying Zhang,1,* Qi Zhou,1 Shui-yan Wu,1 Ye Zhao,2 Wei-ying Gu,3 Jian Pan,1 Jian-nong Cen,2 Zi-xing Chen,2 Wen-ge Guo,4 Chien-shing Chen,5 Wen-hua Yan,6 Shao-yan Hu1 1Department of Haematology and Oncology, Children’s Hospital of Soochow University, 2Department of Haematology, The First Affiliated Hospital of Soochow University, Suzhou, 3Department of Haematology, The Third Affiliated Hospital of Soochow University, Changzhou, People’s Republic of China; 4Department of Mathematical Sciences, New Jersey Institute of Technology, Newark, NJ, 5Department of Internal Medicine, Division of Hematology and Medical Oncology and Biospecimen Laboratory, Loma Linda University, Loma Linda, CA, USA; 6Department of Cardiology, Children’s Hospital of Soochow University, Suzhou, People’s Republic ofChina *These authors contributed equally tothis work Abstract: S100A8 has been increasingly recognized as a biomarker in multiple solid tumors and has played pivotal roles in hematological malignancies. S100A8 is potentially an indicator for poor survival in acute myeloid leukemia (AML) in retrospective studies. However, the mechanisms of S100A8 are diverse in cancers. In this study, we investigated the correlation of S100A8 at the transcription level with clinical parameters in 91 de novo AML patients and explored its mechanisms of chemoresistance to etoposide in vitro. The transcription level of S100A8 was significantly lower at initial and relapse stages of AML samples than at complete remission (P

Details

Language :
English
ISSN :
11786930
Database :
OpenAIRE
Journal :
OncoTargets and Therapy
Accession number :
edsair.doi.dedup.....a1cc65fc27db976a385291dfd719f7d0